Ticketplus CFO awarded 153,846 new shares

Ticketplus Ltd. (TP) reported that Chief Financial Officer Jadue Musalem Joaquin Nicolas acquired 153,846 Ordinary Shares on 2026-08-10 through a grant or award.

Accepted by SEC EDGAR 08/10/2026 - 05:28 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ticketplus Ltd. (TP) reported that Chief Financial Officer Jadue Musalem Joaquin Nicolas acquired 153,846 Ordinary Shares on 2026-08-10 through a grant or award. The shares are held indirectly by Medistat SpA, over which he serves as general manager with sole voting and dispositive power. Following this transaction, his indirect holdings reported in this form total 153,846 Ordinary Shares.

Insider Trade Summary

Grant/Award: 153,846 shares

Grant/Award 1 txn

Insider Jadue Musalem Joaquin Nicolas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	153,846	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 153,846 shares (Indirect, By Medistat SpA)

Footnotes (1)

1. F1. The reporting person is the general manager of Medistat SpA and has sole voting and dispositive power over the shares held by Medistat SpA.

Key Figures

Shares acquired: 153,846 Ordinary Shares Price per share: $0.00 Shares held after transaction: 153,846 Ordinary Shares

3 metrics

Shares acquired 153,846 Ordinary Shares Non-derivative grant/award on 2026-08-10, transaction code A

Price per share $0.00 Reported transaction price per share for the award of Ordinary Shares

Shares held after transaction 153,846 Ordinary Shares Total indirect holdings reported following the grant, held by Medistat SpA

Key Terms

Grant, award, or other acquisition, indirect ownership, voting and dispositive power

3 terms

Grant, award, or other acquisition financial

"Transaction code A is described as a Grant, award, or other acquisition"

indirect ownership financial

"The shares are reported with ownership type indirect by Medistat SpA"

voting and dispositive power financial

"Footnote states sole voting and dispositive power over shares held"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ticketplus Ltd. (TP) disclose for its CFO?

Ticketplus Ltd. reported that its CFO, Jadue Musalem Joaquin Nicolas, received a grant of 153,846 Ordinary Shares on 2026-08-10. The acquisition was reported as a non-derivative award at a per-share price of $0.00.

How many Ticketplus Ltd. (TP) shares does the CFO hold after this Form 4 transaction?

After the reported transaction, the CFO’s indirect holdings total 153,846 Ordinary Shares. This figure reflects the shares held through Medistat SpA as disclosed, all of which are attributed to this grant or award.

Was the Ticketplus Ltd. (TP) CFO’s Form 4 transaction a purchase or an award?

The transaction was reported as a grant, award, or other acquisition of Ordinary Shares, not an open-market purchase. It used transaction code A, indicating an award-type acquisition at a stated price of $0.00 per share.

How are the Ticketplus Ltd. (TP) shares held by the CFO structured?

The 153,846 Ordinary Shares are held indirectly through Medistat SpA. A footnote explains the CFO is Medistat SpA’s general manager and has sole voting and dispositive power over those shares held by the entity.

Were the Ticketplus Ltd. (TP) CFO’s reported shares acquired under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is marked as false, indicating the transaction was not affirmed as made under a trading plan. The filing describes the event as a grant or award of 153,846 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jadue Musalem Joaquin Nicolas

(Last) (First) (Middle)

C/O TICKETPLUS LTD. ALONSO DE CORDOVA

5320, PISO 16, LAS CONDES

(Street)

SANTIAGO

(City) (State) (Zip)

CHILE

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ticketplus Ltd. [ TP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/10/2026		A		153,846	A	$0	153,846	I	By Medistat SpA(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is the general manager of Medistat SpA and has sole voting and dispositive power over the shares held by Medistat SpA.

	/s/ Joaquin Nicolas Jadue Musalem	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)